skip to content

Market News

Shire upgraded by HSBC

06 July 2017 15:22

HSBC has adopted a more moderate stance on biotech company Shire (LON:SHP) and moved to a hold rating (from reduce), believing the haemophilia headline risk is now largely priced in.

Nevertheless, the bank highlighted that other risks remain and commented:

"Although we view the near-term haemophilia headline as in the price, other risks - Haven-3 data in Q4, which may be more material, the risk of the group's tax rate increasing, risk of Baxter-related tax indemnification, longer-term price pressure and competition in haemophilia and hereditary angioedema (HAE) - remain and investors need to be cognizant."

HSBC also said that, while upgrading to a hold position, it remains unimpressed with the returns profile of the company, especially considering its balance sheet gearing.

Analysts have left their target unchanged at £44.50 per share.

At 3:22pm: (LON:SHP) Shire PLC share price was -57p at 4276.5p

Story provided by

Related Company: SHP

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

Bluezest Aviva Aberdeen

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.